Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.
Rodolfo J Galindo, Bobak Moazzami, Amany Gerges et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized clinical trial evaluated the effectiveness of real-time continuous glucose monitoring (rtCGM) versus capillary blood glucose (CBG) testing in adults with type 2 diabetes and end-stage kidney failure undergoing hemodialysis. The study found no significant difference in the percentage of time below range (<70 mg/dL), but rtCGM improved percentage time in range (63.4% vs 54.5%) and reduced percentage time above range (>180 mg/dL) (35.3% vs 44.3%).
Key findings
- No significant difference in %TBR <70 mg/dL between rtCGM and CBG (1.17% vs 1.29%; P = 0.28).
- Percentage time in range (%TIR) was higher with rtCGM (63.4% vs 54.5%; P ≤ 0.01).
- Mean glucose levels were lower with rtCGM (173.6 mg/dL vs 187.7 mg/dL; P ≤ 0.01).
- Percentage time above range (%TAR) >180 mg/dL decreased with rtCGM (35.3% vs 44.3%; P ≤ 0.01).
Why it matters
Improved glycemic control is crucial for patients with type 2 diabetes and end-stage kidney failure. This study suggests that rtCGM may enhance monitoring by increasing time in range and reducing hyperglycemia, potentially leading to better management of diabetes in this vulnerable population.